128 related articles for article (PubMed ID: 28692456)
1. Focal necrotizing myopathy with 'dropped-head syndrome' induced by cobimetinib in metastatic melanoma.
Gauci ML; Laly P; Leonard-Louis S; Behin A; Gottlieb J; Madelaine-Chambrin I; Baroudjian B; Da-Meda L; Mourah S; Battistella M; Basset-Seguin N; Bagot M; Pages C; Vercellino L; Maisonobe T; Lebbé C
Melanoma Res; 2017 Oct; 27(5):511-515. PubMed ID: 28692456
[TBL] [Abstract][Full Text] [Related]
2. The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.
Amaral T; Nouri N; Garbe C
Expert Rev Anticancer Ther; 2016 Jul; 16(7):705-15. PubMed ID: 27219630
[TBL] [Abstract][Full Text] [Related]
3. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
[TBL] [Abstract][Full Text] [Related]
4. Cobimetinib: inhibiting MEK1/2 in BRAF V600-mutant melanoma.
Eagles JR; Jimeno A
Drugs Today (Barc); 2016 Nov; 52(11):593-605. PubMed ID: 28112278
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
[TBL] [Abstract][Full Text] [Related]
6. Posterior reversible encephalopathy syndrome due to combination of vemurafenib and cobimetinib for metastatic melanoma.
Boukari F; Dugourd PM; Chassang M; Mondot L; Passeron T; Lacour JP; Montaudie H
Pigment Cell Melanoma Res; 2017 Mar; 30(2):262-264. PubMed ID: 27885826
[No Abstract] [Full Text] [Related]
7. Cobimetinib (GDC-0973, XL518).
Andrlová H; Zeiser R; Meiss F
Recent Results Cancer Res; 2018; 211():177-186. PubMed ID: 30069767
[TBL] [Abstract][Full Text] [Related]
8. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
Ascierto PA; McArthur GA; Dréno B; Atkinson V; Liszkay G; Di Giacomo AM; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Yan Y; Wongchenko M; Chang I; Hsu JJ; Koralek DO; Rooney I; Ribas A; Larkin J
Lancet Oncol; 2016 Sep; 17(9):1248-60. PubMed ID: 27480103
[TBL] [Abstract][Full Text] [Related]
9. [Vemurafenib-induced radiation recall dermatitis].
Greliak A; Le Guern A; Bataille M; Lebas D; Wiart T; Modiano P
Ann Dermatol Venereol; 2019 May; 146(5):382-384. PubMed ID: 30981540
[TBL] [Abstract][Full Text] [Related]
10. A novel side effect of mitogen-activated protein kinase inhibitor cobimetinib: Acute corneal decompensation.
Asfuroglu M; Asfuroğlu Y
Indian J Ophthalmol; 2019 Dec; 67(12):2073-2075. PubMed ID: 31755464
[TBL] [Abstract][Full Text] [Related]
11. New primary melanoma in a patient under triple therapy with vemurafenib, cobimetinib, and atezolizumab for metastatic melanoma.
Diamantopoulos PT; Lakiotaki E; Kyriakakis G; Gogas H
Melanoma Res; 2020 Apr; 30(2):206-208. PubMed ID: 31157737
[TBL] [Abstract][Full Text] [Related]
12. Adjunction of a MEK inhibitor to Vemurafenib in the treatment of metastatic melanoma results in a 60% reduction of acute kidney injury.
Teuma C; Pelletier S; Amini-Adl M; Perier-Muzet M; Maucort-Boulch D; Thomas L; Laville M; Fouque D; Dalle S
Cancer Chemother Pharmacol; 2017 May; 79(5):1043-1049. PubMed ID: 28396940
[TBL] [Abstract][Full Text] [Related]
13. MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors.
Grimaldi AM; Simeone E; Festino L; Vanella V; Strudel M; Ascierto PA
Am J Clin Dermatol; 2017 Dec; 18(6):745-754. PubMed ID: 28537004
[TBL] [Abstract][Full Text] [Related]
14. Cardiac toxicity of combined vemurafenib and cobimetinib administration
.
Fiocchi R; Gori M; Taddei F; Trevisani L; Gallo M; Eleftheriou G
Int J Clin Pharmacol Ther; 2019 May; 57(5):259-263. PubMed ID: 30704555
[TBL] [Abstract][Full Text] [Related]
15. Two cases of pneumonitis induced by targeted therapy.
Lafabregue E; Arnault JP; Auquier M; Magois E; Chaby G; Lok C
Melanoma Res; 2019 Aug; 29(4):441-443. PubMed ID: 31260421
[TBL] [Abstract][Full Text] [Related]
16. Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma.
Keating GM
Drugs; 2016 Apr; 76(5):605-15. PubMed ID: 26984388
[TBL] [Abstract][Full Text] [Related]
17. Drug reaction with eosinophilia and systemic symptoms syndrome induced by combination of vemurafenib and cobimetinib in melanoma: A series of 11 cases.
Brégeon B; Bernier C; Josselin N; Peuvrel L; Le Moigne M; Saint-Jean M; Quéreux G
J Am Acad Dermatol; 2019 Feb; 80(2):558-562. PubMed ID: 30081108
[No Abstract] [Full Text] [Related]
18. Gene Expression Profiling in
Wongchenko MJ; McArthur GA; Dréno B; Larkin J; Ascierto PA; Sosman J; Andries L; Kockx M; Hurst SD; Caro I; Rooney I; Hegde PS; Molinero L; Yue H; Chang I; Amler L; Yan Y; Ribas A
Clin Cancer Res; 2017 Sep; 23(17):5238-5245. PubMed ID: 28536307
[No Abstract] [Full Text] [Related]
19. Cobimetinib: First Global Approval.
Garnock-Jones KP
Drugs; 2015 Oct; 75(15):1823-30. PubMed ID: 26452567
[TBL] [Abstract][Full Text] [Related]
20. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]